Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avian and seasonal influenza vaccine induced immune responses
2023-509178-44-00Phase 4Authorised
- Sponsor
- Finnish Institute for Health and Welfare
- Start
- Apr 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of Audenz, aH5N8c, influenza virus type B (Victoria), Fluzone Trivalent, Vaxigrip and 1 more in Avian Influenza (AI) and seasonal influenza, sponsored by Finnish Institute for Health and Welfare. Primary endpoint: Seroconversion proportion after second avian influenza vaccine dose. Planned start Apr 2024; status: authorised.
02
Drugs
AudenzaH5N8cinfluenza virus type B (Victoria)Fluzone TrivalentVaxigrip
03
Conditions
Avian Influenza (AI)seasonal influenza
Beyond the preview
Go deeper on 2023-509178-44-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509178-44-00.